Q1 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Innovation: Pipeline overview
Appendix
Innovation: Clinical trials
References
Abbreviations
20+ potential billion USD+ pipeline assets with approval by 2026
Most are supported by high strength of evidence
Selected assets
Unprobabilized
peak sales
USD bn / multi-bn
Strength of evidence
Moderate
Sabatolimab
MDS; AML
NIS793
PDAC; Colorectal Cancer
Pelacarsen
CVRR
Canakinumab
Adj. NSCLC
Ociperlimab¹
NSCLC
UNR844
Presbyopia
Libvatrep (SAF312)
Chronic Ocular Surface Pain
TNO155, JDQ443²
NSCLC; Colorectal Cancer;
Combos
Iptacopan
PNH; C3G; IgAN; aHUS
Remibrutinib
CSU; MS
Zolgensma
SMA IT
Ligelizumab
FA
Ociperlimab
NSCLC
Strength of evidence
High
Kisqali
Adj. BC (+endocrine th.)
YTB323²
2L DLBCL
lanalumab
Sjogren's; SLE; AIH;
Lupus Nephritis
Ensovibep
Coronavirus infection
Leqvio
Hypercholesterolemia
Cosentyx
Multiple indications
Pluvicto
✓ mCRPC post-taxane;
mCRPC pre-taxane; mHSPC
Scemblix
✓ 3L+ CML;
1L CML
Tislelizumab
Multiple indications
Piqray (alpelisib)
✓ PROS; HER2+ adv BC;
TNBC; ovarian cancer
Most advanced and
key indication(s)
approved by 2026
Submission
Phase III
Phase II
LCM
✓ Approved
Unprobabilized
peak sales
up to USD 1bn
Lutathera
1L G2/G3 NET
Kymriah
r/r Follicular Lymphoma
Tafinlar/Mekinist
Solid Tumor Agnostic
Beovu
DME
Jakavi
SR GvHD
Strength of evidence based on the most advanced indication: High if in Ph3 or when Ph2 results available for the same MoA in the lead indication.
1. BeiGene option deal. 2. Ph3 to start in 2022. Assets are shown in the phase of the most advanced indication (listed first). Value based on the total of the listed indication(s).
35 Investor Relations | Q1 2022 Results
U NOVARTIS | Reimagining MedicineView entire presentation